Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Taiho Gets Options to French Firm’s GnT-V-Targeted Cancer Drug in Asia
August 28, 2023
- FDA Grants Priority Review for Xtandi in Earlier Type of Prostate Cancer
August 25, 2023
- Ayumi Walks Away from JPMA, Plans to Join JGA
August 23, 2023
- Mounjaro Makes Comeback as No 1 in GP Promotion, Tarlige Tops HP List in June: Intage
August 23, 2023
- Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
August 23, 2023
- Iveric Bio’s AMD Drug Accepted for EMA Review: Astellas
August 21, 2023
- Opdivo Yet Again Frontrunner, Keytruda Follows in April-June: IQVIA
August 18, 2023
- Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
- Takeda Files cTTP Therapy ADAMTS-13 in Japan
August 18, 2023
- Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
August 17, 2023
- BMS Unit Wins Japan Approval for Sprycel Authorized Generic
August 17, 2023
- Healios Sets Up R&D Subsidiary for eNK Cells
August 16, 2023
- Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
August 14, 2023
- Novo Nordisk Files Once-Weekly Basal Insulin in Japan
August 10, 2023
- Astellas to Open New Life Sciences Facility in Greater Boston Area
August 10, 2023
- Japan Ethical Drug Sales Up 8.8% in June: Crecon
August 10, 2023
- Nippon Shinyaku Gets EU Orphan Tag for Myelofibrosis Med
August 9, 2023
- Otsuka Unit Astex, Merck Expand Drug Discovery Alliance
August 9, 2023
- Astellas Puts Up US$50 Million for CAR-T Player Poseida
August 9, 2023
- Astellas Set to Cut Development Time with Cell Culture Robot, Eyes 4 Billion Yen Profit per Product
August 9, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…